Clinical Summary
Clinical Summary: Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial
Many patients with major depressive disorder remain symptomatic despite an adequate antidepressant trial, and specialty-care clinicians often have no clear next step beyond further medication changes. This trial addresses whether adding cognitive-behavioral therapy to ongoing medication management improves outcomes in pharmacotherapy-resistant depression treated in psychiatric specialty care.
Design
A 16-week assessor-masked randomized controlled trial with a 12-month follow-up
N
A total of 80 patients were randomized; 78 (97.5%) were assessed for the primary outcome, and 73 (91.3%) were followed up for 12 months.
Population
Outpatients aged 20-65 years with pharmacotherapy-resistant depression (taking antidepressant medications for ≥ 8 weeks, 17-item GRID-Hamilton Depression Rating Scale [GRID-HDRS17] score ≥ 16, Maudsley Staging Method for treatment-resistant depression score ≥ 3, and DSM-IV criteria for major depressive disorder)
Duration
A 16-week assessor-masked randomized controlled trial with a 12-month follow-up
Key Findings
- At 16 weeks, supplementary CBT produced greater improvement in clinician-rated depressive symptoms than treatment as usual alone, with least squares mean changes in GRID-HDRS17 scores of −12.7 vs −7.4; difference = −5.4; 95% CI, −8.1 to −2.6; P < .001.
- The benefit persisted at 12 months, with least squares mean changes in GRID-HDRS17 scores of −15.4 vs −11.0; difference = −4.4; 95% CI, −7.2 to −1.6; P = .002.
- Participants allocated to the CBT group were 2.4 times more likely to have a treatment response at 16 weeks than members of the TAU group (RR = 2.38; 95% CI, 1.48 to 3.84), resulting in an NNT of 5 (95% CI, 3 to 83).
- Supplementary CBT significantly improved remission at 16 weeks (RR = 2.13; 95% CI, 1.04 to 4.35; NNT = 5; 95% CI, 3 to 36), and this was maintained over 12 months except at 3 months (RR = 1.67; 95% CI, 0.95 to 2.93).
- There was no early separation at 8 weeks on the primary outcome (P = .11), and self-rated depressive symptoms and quality-of-life outcomes showed no statistically significant between-group differences at each time point.
Clinical Bottom Line
For pharmacotherapy-resistant major depressive disorder in psychiatric specialty care, adding CBT to usual medication management improves clinician-rated depressive symptoms, response, and remission, with benefits sustained for at least 12 months. Adjunctive CBT is a viable next-step treatment option when antidepressant medication alone is not enough.
Practice Implications
- Offer adjunctive cognitive-behavioral therapy as an augmentation strategy for patients with pharmacotherapy-resistant depression who remain symptomatic despite taking antidepressant medications for ≥ 8 weeks.
- Set expectations that measurable benefit may not be evident by 8 weeks; in this trial, the primary outcome was not different at 8 weeks (P = .11) but was clearly different by 16 weeks.
- Track both clinician-rated and patient-reported outcomes during follow-up, because GRID-HDRS17 improved significantly while BDI-II, QIDS-SR, and SF-36 measures showed no statistically significant between-group differences at each time point.
- Use response and remission data to frame treatment discussions: at 16 weeks, both outcomes yielded an NNT of 5, which helps communicate the practical value of adding CBT to usual medication management.
